Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 |
| | 8-K | 10-K | 8-K | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Revenues: |
| International | | | | 241.3 | 230.3 | 219.8 | 210.4 | 196.5 |
| Neuro | | | | 341.0 | 339.8 | 338.7 | 328.1 | 319.3 |
| Vascular | | | | 465.4 | 442.5 | 408.9 | 382.4 | 352.1 |
| Total revenues | 884.6 | 847.1 | 829.9 | 806.4 | 782.3 | 747.6 | 710.5 | 671.4 |
| Revenue growth [+] | 13.1% | 13.3% | 16.8% | 20.1% | 32.1% | 33.4% | 31.9% | 27.4% |
| International | | | | 22.8% | | | | |
| Neuro | | | | 6.8% | 15.3% | 15.7% | 10.0% | 4.5% |
| Vascular | | | | 32.2% | 48.6% | 52.7% | 59.0% | 58.9% |
| Cost of goods sold | 325.8 | 311.9 | 307.7 | 299.6 | 290.8 | 272.2 | 266.2 | 256.2 |
| Gross profit | 558.9 | 535.2 | 522.2 | 506.8 | 491.5 | 475.4 | 444.2 | 415.3 |
| Gross margin | 63.2% | 63.2% | 62.9% | 62.9% | 62.8% | 63.6% | 62.5% | 61.8% |
| Selling, general and administrative [+] | 461.9 | 449.7 | 447.6 | 433.4 | 409.4 | 378.3 | 341.4 | 323.2 |
| Sales and marketing | 346.3 | | 334.1 | 319.9 | 295.9 | | 264.8 | 246.6 |
| General and administrative | | 115.6 | | | | 113.5 | | |
| Research and development | 78.8 | 79.4 | 113.4 | 108.9 | 107.0 | 104.6 | 72.0 | 90.2 |
| EBITDA [+] | | 42.1 | | -18.1 | -10.0 | 5.3 | | 15.7 |
| EBITDA growth | -584.8% | 697.5% | -151.8% | -215.0% | -21.3% | -120.2% | -329.4% | -7.5% |
| EBITDA margin | 5.5% | 5.0% | -2.6% | -2.2% | -1.3% | 0.7% | 5.8% | 2.3% |
| Depreciation | | 31.9 | | 11.0 | 10.4 | 9.9 | 9.4 | 12.7 |
| EBITA | 20.2 | 10.2 | -32.7 | -29.1 | -20.4 | -4.6 | 31.9 | 3.0 |
| EBITA margin | 2.3% | 1.2% | -3.9% | -3.6% | -2.6% | -0.6% | 4.5% | 0.4% |
| Amortization of intangibles | | | | 6.4 | 4.7 | 2.9 | 1.1 | 1.1 |
| EBIT [+] | 18.1 | 6.1 | -38.8 | -35.5 | -25.0 | -7.5 | 30.8 | 1.9 |
| EBIT growth | -172.5% | -181.1% | -226.0% | -1994.3% | -4.1% | -80.7% | -215.8% | -71.3% |
| EBIT margin | 2.1% | 0.7% | -4.7% | -4.4% | -3.2% | -1.0% | 4.3% | 0.3% |
| Interest income, net [+] | 0.4 | -0.2 | -0.1 | 0.0 | 0.4 | 0.9 | 1.4 | 1.6 |
| Interest expense | | 0.3 | 0.2 | 0.1 | 0.0 | | | |
| Interest income | 0.7 | 0.1 | | | | 0.9 | 1.4 | 1.6 |
| Other income (expense), net | -0.9 | -2.0 | -5.2 | -4.0 | -3.5 | -3.9 | -2.2 | -1.1 |
| Pre-tax income | 17.6 | 3.9 | -44.2 | -39.4 | -28.1 | -10.5 | 29.9 | 2.4 |
| Income taxes | 11.2 | 5.9 | -13.7 | -19.2 | -19.8 | -13.1 | 0.1 | -9.6 |
| Tax rate | 63.3% | 151.4% | 31.0% | | 70.7% | 125.0% | | -393.5% |
| Minority interest | | | | | | | -3.7 | -3.9 |
| Net income | 6.5 | -2.0 | -30.5 | -19.4 | -6.5 | 5.3 | 33.6 | 15.9 |
| Net margin | 0.7% | -0.2% | -3.7% | -2.4% | -0.8% | 0.7% | 4.7% | 2.4% |
| |
| Basic EPS [+] | $0.17 | ($0.05) | ($0.81) | ($0.52) | ($0.17) | $0.14 | $0.92 | $0.44 |
| Growth | -197.7% | -136.8% | -187.6% | -218.3% | 18.7% | -132.6% | -438.0% | 44.4% |
| Diluted EPS [+] | $0.17 | ($0.05) | ($0.80) | ($0.51) | ($0.17) | $0.14 | $0.90 | $0.43 |
| Growth | -198.6% | -137.1% | -188.9% | -218.4% | 17.1% | -132.2% | -437.5% | 46.6% |
| |
| Shares outstanding (basic) [+] | 38.0 | 37.8 | 37.7 | 37.4 | 37.1 | 36.8 | 36.3 | 36.2 |
| Growth | 2.5% | 2.9% | 3.7% | 3.1% | 3.1% | 3.3% | 2.8% | 3.5% |
| Shares outstanding (diluted) [+] | 38.4 | 38.3 | 38.0 | 37.9 | 37.8 | 37.5 | 37.1 | 36.8 |
| Growth | 1.5% | 2.1% | 2.3% | 3.0% | 4.4% | 4.5% | 3.0% | 1.9% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|